Enocitabine

Chemical structure of Enocitabine

Enocitabine is a chemotherapy agent used in the treatment of certain types of cancer. It is a prodrug of cytarabine, which means it is converted into cytarabine in the body. Enocitabine is primarily used in the treatment of acute myeloid leukemia (AML) and other hematological malignancies.

Mechanism of Action

Enocitabine is metabolized into cytarabine, which is an antimetabolite that interferes with DNA synthesis. Cytarabine is incorporated into DNA during the S-phase of the cell cycle, leading to the inhibition of DNA polymerase and ultimately causing cell death. This makes it effective against rapidly dividing cancer cells.

Administration

Enocitabine is administered intravenously. The dosage and schedule depend on the specific treatment protocol and the patient's condition. It is often used in combination with other chemotherapy agents to enhance its efficacy.

Side Effects

Common side effects of enocitabine include:

• Myelosuppression: A decrease in the production of blood cells, leading to anemia, leukopenia, and thrombocytopenia.
• Nausea and vomiting
• Diarrhea
• Mucositis: Inflammation of the mucous membranes in the digestive tract.
• Alopecia: Hair loss.

Pharmacokinetics

Enocitabine is rapidly converted to cytarabine in the body. Cytarabine is then metabolized primarily in the liver and excreted in the urine. The half-life of cytarabine is relatively short, which necessitates frequent dosing or continuous infusion to maintain therapeutic levels.

Related pages

• Cytarabine
• Chemotherapy
• Acute myeloid leukemia
• Antimetabolite